PE20080669A1 - Composicion de liberacion sostenida que comprende levodopa - Google Patents
Composicion de liberacion sostenida que comprende levodopaInfo
- Publication number
- PE20080669A1 PE20080669A1 PE2007001186A PE2007001186A PE20080669A1 PE 20080669 A1 PE20080669 A1 PE 20080669A1 PE 2007001186 A PE2007001186 A PE 2007001186A PE 2007001186 A PE2007001186 A PE 2007001186A PE 20080669 A1 PE20080669 A1 PE 20080669A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- weight
- amount
- acid
- levodopa
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004502 levodopa Drugs 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical class O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 210000004051 gastric juice Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 abstract 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 229960001126 alginic acid Drugs 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 150000004781 alginic acids Chemical class 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
- 239000001569 carbon dioxide Substances 0.000 abstract 1
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract 1
- 239000003954 decarboxylase inhibitor Substances 0.000 abstract 1
- 238000005188 flotation Methods 0.000 abstract 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 239000001630 malic acid Substances 0.000 abstract 1
- 235000011090 malic acid Nutrition 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) LEVODOPA EN UNA CANTIDAD DE 10% A 50% EN PESO DE LA COMPOSICION; B) UN INHIBIDOR DE LA DESCARBOXILASA TAL COMO CARBIDOPA DONDE LA RELACION DE LEVODOPA Y CARBIDOPA ES DE 20:1 A 2:1; C) UNA MATRIZ DE LIBERACION SOSTENIDA PARA LA LEVODOPA QUE CONTIENE UN AGENTE EXPANSOR TAL COMO POLIMEROS CELULOSICOS EN UNA CANTIDAD DE 5% A 60% EN PESO DE LA COMPOSICION Y QUE ACTUAN EN PRESENCIA DEL JUGO GASTRICO; D) UN AGENTE QUE GENERA GAS EN PRESENCIA DEL JUGO GASTRICO TAL COMO SALES MONO Y DIBASICAS DEL ACIDO CARBONICO EN UNA CANTIDAD DE 3% A 15% EN PESO DE LA COMPOSICION QUE ES UTIL PARA AUMENTAR LA CAPACIDAD DE FLOTACION DE LA COMPOSICION EN EL JUGO SIENDO EL DIOXIDO DE CARBONO EL GAS GENERADO; E) UN AGENTE FORMADOR DE MEMBRANA IMPERMEABLE AL GAS FORMADO QUE CONTIENE ACIDO ALGINICO Y ALGINATO DE SODIO EN UNA CANTIDAD DE 10% A 60% EN PESO DE LA COMPOSICION; F) UN ACIDO ORGANICO TAL COMO ACIDO CITRICO, ACIDO FUMARICO, ACIDO MALICO, ENTRE OTROS, EN UNA CANTIDAD DE 1,5% A 6% EN PESO DE LA COMPOSICION PARA ESTABILIZAR LA CARBIDOPA. DICHA COMPOSICION FARMACEUTICA ES DE LIBERACION PROLONGADA SIENDO UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82498506P | 2006-09-08 | 2006-09-08 | |
| US82827606P | 2006-10-05 | 2006-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080669A1 true PE20080669A1 (es) | 2008-07-18 |
Family
ID=39157983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001186A PE20080669A1 (es) | 2006-09-08 | 2007-09-05 | Composicion de liberacion sostenida que comprende levodopa |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080139655A1 (es) |
| AR (1) | AR062659A1 (es) |
| CL (1) | CL2007002574A1 (es) |
| PE (1) | PE20080669A1 (es) |
| WO (1) | WO2008030830A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9161911B2 (en) | 2008-08-15 | 2015-10-20 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PT3116475T (pt) | 2014-03-13 | 2020-12-15 | Neuroderm Ltd | Composições de inibidores de dopa-descarboxilase |
| MA47686A (fr) * | 2017-03-01 | 2021-05-12 | Arena Pharm Inc | Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés |
| CN109439645B (zh) * | 2018-10-31 | 2022-07-19 | 武汉工程大学 | 利用锐孔法制备解磷微生物缓释海藻酸钠微球的方法 |
| WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| CA3187827A1 (en) * | 2020-06-30 | 2022-01-06 | Imbria Pharmaceuticals, Inc. | Modified release formulations of modified forms of trimetazidine |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| AU6872201A (en) * | 2000-06-23 | 2002-01-08 | Teva Pharma | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| US6531153B2 (en) * | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| KR20050083750A (ko) * | 2002-10-11 | 2005-08-26 | 디포메드 디벨롭먼트 리미티드 | 위-체류성 레보도파 전달 형태 |
| US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
-
2007
- 2007-09-05 US US11/850,063 patent/US20080139655A1/en not_active Abandoned
- 2007-09-05 PE PE2007001186A patent/PE20080669A1/es not_active Application Discontinuation
- 2007-09-05 WO PCT/US2007/077572 patent/WO2008030830A2/en not_active Ceased
- 2007-09-05 AR ARP070103916A patent/AR062659A1/es unknown
- 2007-09-05 CL CL200702574A patent/CL2007002574A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080139655A1 (en) | 2008-06-12 |
| AR062659A1 (es) | 2008-11-26 |
| CL2007002574A1 (es) | 2008-05-23 |
| WO2008030830A3 (en) | 2008-05-29 |
| WO2008030830A2 (en) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080669A1 (es) | Composicion de liberacion sostenida que comprende levodopa | |
| ES2583988T3 (es) | Procedimiento para producir una solución acuosa de ácido cloroso para uso como bactericida | |
| AR063732A1 (es) | Composicion estabilizada para producir dioxido de cloro | |
| MX2010007295A (es) | Composiciones acuosas estables de ciclosporina. | |
| PE20070691A1 (es) | Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberacion modificada | |
| PE20190914A1 (es) | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico | |
| NZ628162A (en) | Use of a natural metabolite to increase crop production | |
| PE20130063A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| GEP20156366B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| PE20080374A1 (es) | Composiciones farmaceuticas de ropinirol | |
| NZ708247A (en) | Hyaluronic acid based formulations | |
| PE20061107A1 (es) | Composiciones de tigeciclina y metodos para su preparacion | |
| BRPI0500704A (pt) | composições de tratamento pessoal reidratáveis | |
| CR20150174A (es) | Composición esterilizada que comprende al menos un ácido hialuronico y ascorbil fosfato de magnesio | |
| TW200716584A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| MX2009013507A (es) | Composiciones libres de conservador que comprenden acido cinamico o acido anisico y benzaldehido o un derivado del mismo. | |
| PE20120599A1 (es) | Metodo para producir material de sabor | |
| BR112012020731A2 (pt) | pastilhas gelatinosas suaves com nicotina. | |
| AR094012A1 (es) | Composiciones estables con peroxido para el cuidado oral | |
| PE20110060A1 (es) | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida | |
| SG165315A1 (en) | Alpha2c adrenoreceptor agonists | |
| AR064288A1 (es) | Fluoresceina sustancialmente pura | |
| MX338643B (es) | Sistema y metodos para generar dioxido de cloro. | |
| PE20140962A1 (es) | Una formulacion farmaceutica solida | |
| AR083166A1 (es) | Derivados de alquil-piperazin-fenil 4(3h)-quinazolinonas utiles para tratar depresion, ansiedad, disfunciones sexuales femeninas y otras patologias del sistema nervioso central, y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |